European Radiology:鉴别肿块型慢性胰腺炎与胰腺癌的放射组学列线图

2022-08-13 shaosai MedSci原创

目前,放射组学可以将成像数据转化为高维特征空间,并利用该空间预测PDAC的肿瘤分期、分级、治疗效果和预后。

慢性胰腺炎(CP)定义为长期的胰腺炎症导致外分泌实质不可逆转的损害和纤维化。CP在形态上的特点是大量的纤维化取代了被破坏的实质,导致胰腺萎缩。然而,CP有时也可能导致胰腺肿大。如果这种肿大表现为局灶性,称为肿块形成型CP(MFCP),胰腺导管腺癌(PDAC)鉴别困难

此外,与正常胰腺患者相比,CP患者患胰腺癌的风险明显增加。PDAC和MFCP的临床表现、危险因素、影像学特征和实验室结果都有重叠,因此这两个实体之间的区分往往具有挑战性。延迟诊断可能会导致早期PDAC的进展,并可能迅速变得无法切除,将MFCP误诊为PDAC可能导致不必要的手术。

目前,放射组学可以将成像数据转化为高维特征空间,并利用该空间预测PDAC的肿瘤分期、分级、治疗效果和预后。然而,很少有放射组学研究评估MFCP和PDAC之间的鉴别诊断。

近日,发表在European Radiology杂志开发并验证了一个CT列线图和基于CT的放射组学特征以区分CP患者的MFCP和PDAC,并期评估了应用于常规多排CT时的价值。

本项研究对本机构治疗的138名经组织病理学诊断的MFCP或PDAC患者的数据进行了回顾性分析。两位放射科医生根据预定的标准分析了原始的CT图像。使用图像分割、特征提取、特征还原和选择创建放射组学模型。CT和放射组学模型是利用103名连续患者的训练队列的数据建立的。这些模型在35名连续患者中得到了验证。通过多变量逻辑回归分析,建立了MFCP和PDAC的鉴别诊断模型,并以列线图的形式显示。根据其鉴别能力和临床实用性,确定了列线图的性能。 

患者的平均年龄为53.7岁,75.4%为男性。CT列线图在训练(曲线下面积[AUC],0.87)和验证(AUC,0.94)队列中显示出对两种病变的良好区分。放射学列线图在训练(AUC,0.91)和验证(AUC,0.93)队列中显示出良好的区分性。决策曲线分析显示,如果阈值概率分别为0.05-0.85和>0.05,患者可以从CT和放射组学列线图中获益。 


 CT和放射学模型的决策曲线分析。红线代表CT模型,绿线代表放射组学模型,黑线代表假设所有患者都有肿块形成的慢性胰腺炎(MFCP),灰色线代表所有假设患者都有胰腺导管腺癌(PDAC),X轴代表阈值概率。验证队列中的决策曲线表明,如果CT和放射组学模型的阈值概率分别为0.05-0.85和>0.05,使用列线图预测MFCP和PDAC比 "将所有患者作为MFCP治疗 "方案或 "将所有患者作为PDAC治疗 "方案更有利

本研究开发并验证了一个CT和一个基于CT的放射组学模型,两者在区分CP患者的MFCP和PDAC方面都表现得相当准确,在完善这类患者的胰腺肿块管理方面具有很大的临床潜力。

原文出处:

Hao Zhang,Yinghao Meng,Qi Li,et al.Two nomograms for differentiating mass-forming chronic pancreatitis from pancreatic ductal adenocarcinoma in patients with chronic pancreatitis.DOI:10.1007/s00330-022-08698-3

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1981418, encodeId=77c41981418c1, content=<a href='/topic/show?id=15a8319384a' target=_blank style='color:#2F92EE;'>#列线图#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=31938, encryptionId=15a8319384a, topicName=列线图)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7931272, createdName=liuli5079, createdTime=Mon Jul 03 06:49:07 CST 2023, time=2023-07-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1729719, encodeId=84521e29719da, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Tue May 23 14:49:07 CST 2023, time=2023-05-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1412064, encodeId=16c5141206419, content=<a href='/topic/show?id=951b82e63ff' target=_blank style='color:#2F92EE;'>#肿块#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82763, encryptionId=951b82e63ff, topicName=肿块)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c58f2824468, createdName=cnxcy, createdTime=Sun Aug 14 01:49:07 CST 2022, time=2022-08-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1238417, encodeId=c4f3123841e5a, content=好文章,谢谢分享。, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTJlfgys76DEiaNtbYo2re3ibjrUPTRibEXRyFwAB4aAGiave842S0FQDf0wAoaH226NiaSoPPDzhndsf1g/132, createdBy=88b489038, createdName=yangchou, createdTime=Sat Aug 13 08:35:01 CST 2022, time=2022-08-13, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1981418, encodeId=77c41981418c1, content=<a href='/topic/show?id=15a8319384a' target=_blank style='color:#2F92EE;'>#列线图#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=31938, encryptionId=15a8319384a, topicName=列线图)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7931272, createdName=liuli5079, createdTime=Mon Jul 03 06:49:07 CST 2023, time=2023-07-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1729719, encodeId=84521e29719da, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Tue May 23 14:49:07 CST 2023, time=2023-05-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1412064, encodeId=16c5141206419, content=<a href='/topic/show?id=951b82e63ff' target=_blank style='color:#2F92EE;'>#肿块#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82763, encryptionId=951b82e63ff, topicName=肿块)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c58f2824468, createdName=cnxcy, createdTime=Sun Aug 14 01:49:07 CST 2022, time=2022-08-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1238417, encodeId=c4f3123841e5a, content=好文章,谢谢分享。, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTJlfgys76DEiaNtbYo2re3ibjrUPTRibEXRyFwAB4aAGiave842S0FQDf0wAoaH226NiaSoPPDzhndsf1g/132, createdBy=88b489038, createdName=yangchou, createdTime=Sat Aug 13 08:35:01 CST 2022, time=2022-08-13, status=1, ipAttribution=)]
    2023-05-23 feather89
  3. [GetPortalCommentsPageByObjectIdResponse(id=1981418, encodeId=77c41981418c1, content=<a href='/topic/show?id=15a8319384a' target=_blank style='color:#2F92EE;'>#列线图#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=31938, encryptionId=15a8319384a, topicName=列线图)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7931272, createdName=liuli5079, createdTime=Mon Jul 03 06:49:07 CST 2023, time=2023-07-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1729719, encodeId=84521e29719da, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Tue May 23 14:49:07 CST 2023, time=2023-05-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1412064, encodeId=16c5141206419, content=<a href='/topic/show?id=951b82e63ff' target=_blank style='color:#2F92EE;'>#肿块#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82763, encryptionId=951b82e63ff, topicName=肿块)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c58f2824468, createdName=cnxcy, createdTime=Sun Aug 14 01:49:07 CST 2022, time=2022-08-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1238417, encodeId=c4f3123841e5a, content=好文章,谢谢分享。, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTJlfgys76DEiaNtbYo2re3ibjrUPTRibEXRyFwAB4aAGiave842S0FQDf0wAoaH226NiaSoPPDzhndsf1g/132, createdBy=88b489038, createdName=yangchou, createdTime=Sat Aug 13 08:35:01 CST 2022, time=2022-08-13, status=1, ipAttribution=)]
    2022-08-14 cnxcy
  4. [GetPortalCommentsPageByObjectIdResponse(id=1981418, encodeId=77c41981418c1, content=<a href='/topic/show?id=15a8319384a' target=_blank style='color:#2F92EE;'>#列线图#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=31938, encryptionId=15a8319384a, topicName=列线图)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7931272, createdName=liuli5079, createdTime=Mon Jul 03 06:49:07 CST 2023, time=2023-07-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1729719, encodeId=84521e29719da, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Tue May 23 14:49:07 CST 2023, time=2023-05-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1412064, encodeId=16c5141206419, content=<a href='/topic/show?id=951b82e63ff' target=_blank style='color:#2F92EE;'>#肿块#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82763, encryptionId=951b82e63ff, topicName=肿块)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c58f2824468, createdName=cnxcy, createdTime=Sun Aug 14 01:49:07 CST 2022, time=2022-08-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1238417, encodeId=c4f3123841e5a, content=好文章,谢谢分享。, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTJlfgys76DEiaNtbYo2re3ibjrUPTRibEXRyFwAB4aAGiave842S0FQDf0wAoaH226NiaSoPPDzhndsf1g/132, createdBy=88b489038, createdName=yangchou, createdTime=Sat Aug 13 08:35:01 CST 2022, time=2022-08-13, status=1, ipAttribution=)]
    2022-08-13 yangchou

    好文章,谢谢分享。

    0

相关资讯

Nature子刊:浙大易文/周如鸿合作揭示糖基化调控胰腺癌新机制

胰腺癌是一种恶性程度极高的消化系统肿瘤,确诊后患者的五年生存率仅为10%左右。代谢的改变是肿瘤细胞的重要特征之一。肿瘤细胞通过代谢重编程产生其快速增殖所需的物质、能量以及氧化还原力。

Nature:一个基因让胰腺癌“改邪归正”!

美国胰腺癌患者的5年生存率是11%,是名副其实的癌王。

Radiology:CT+CA19-9的强强联手:非转移性胰腺癌的治疗反应评估

总所周知,准确评估治疗反应对于癌症患者的管理非常重要。目前对大多数类型的肿瘤进行反应评估的标准方法是实体瘤反应评估标关于胰腺导管腺癌(PDAC),CT一直是治疗反应评估的主要依据。

Radiology:CT和CA19-9对非转移性胰腺癌治疗效果的评估

于胰腺导管腺癌(PDAC),CT一直是治疗反应评估的主要依据。

Lancet Oncol:尼拉帕利联合伊匹单抗维持治疗可改善晚期胰腺癌患者预后

尼拉帕利联合伊匹单抗作为晚期胰腺癌患者的维持治疗可改善患者预后

全癌种生存性别差异分析:女性在6种癌种中生存更好,而男性仅1种稍佳!

MedComm:男性与女性诊断后的癌症特异性生存率:全癌种分析。